Neurocrine (NBIX) Earnings Dates, Call Summary & Reports

Compare

1,553 Followers

Earnings Data

Report Date

May 06, 2026

After Close (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

1.15

Last Year’s EPS

0.08

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 24 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Feb 11, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed strong commercial execution, robust top-line growth (22% YoY), a very successful first-year launch for CRENESSITY (> $300M and ~10% penetration), solid cash generation (+$700M to $2.5B) and meaningful pipeline momentum (Phase II entry for NBI-'890 and two Phase III neuropsychiatry programs with 2027 readouts). Headwinds include pricing/formulary concessions (≈ -4% pricing impact), higher SG&A/R&D investments to support sales force expansion and late-stage trials, and early-launch variability for CRENESSITY with limited prescriber depth (two-thirds of prescribers have only one treated patient). Overall, positives — strong revenue, cash, differentiated clinical data and a growing pipeline — outweigh the manageable near-term commercial and expense challenges.

Company Guidance

Neurocrine guided that INGREZZA sales are expected to be $2.7–$2.8 billion in 2026 (≈10% growth versus 2025) driven by double‑digit volume growth with net pricing roughly stable versus levels exiting 2025 (Matt cited a ~4% price headwind factored into 2026), an expanded sales force to be in place by end‑Q1 and continued strong NRx momentum and broad access; CRENESSITY had >$300 million of net sales in 2025, reached ~10% of the classic CAH population by year‑end with >1,000 prescribers (≈2/3 of them having treated only one patient), and the company is not providing 2026 sales guidance while highlighting CRENESSITY metrics including >450 patient‑years of trial exposure, >550 patient‑years real‑world exposure, >35,000 patient‑weeks exposure, ~80% retention at 2 years, 0% pediatric adrenal insufficiency (1.6% in adults), ~70% of adults brought into physiologic steroid range, ~40% of overweight/obese patients with ≥5% weight loss at 2 years and a >2‑inch predicted adult height benefit in a prepubertal subset; company‑level 2025 results were >$2.8 billion total product sales (22% YoY growth) with INGREZZA ≈$2.5 billion (9% YoY), cash of ~$2.5 billion (up ~$700M from $1.8B), ~30% non‑GAAP operating margin (~$850M non‑GAAP operating income, including $83M of R&D/IP expense), and 2026 expectations of continued strong non‑GAAP income alongside increased SG&A (GAAP SG&A ~low‑40% of sales at the midpoint) and higher R&D (GAAP R&D ex. ≈$25M milestones ~mid‑30% of sales) as the company advances registrational programs with top‑line Phase III data expected in 2027.

Record Annual Revenue and Strong Top-Line Growth

Total product sales exceeded $2.8 billion in FY2025, representing 22% year-over-year growth versus FY2024.

INGREZZA: Durable Franchise with Double-Digit Volume Growth

INGREZZA generated just over $2.5 billion in revenue in 2025 (up 9% YoY). Management guides INGREZZA sales of $2.7–$2.8 billion for 2026 (~10% growth) driven by double-digit volume growth and an expanded sales force; net pricing expected to be relatively consistent with exit-2025 levels.

CRENESSITY: Very Strong First Full-Year Launch

CRENESSITY delivered more than $300 million in net product sales in its first full commercial year (2025) and reached ~10% of the addressable classic CAH population. Real-world signals include rapid reimbursement, strong refill/persistence behavior, and >550 patient-years of real-world exposure.

Compelling Clinical Differentiation and Safety Data

CRENESSITY open-label extension: durable ACTH and androgen reductions through 2 years, ~80% retention at 2 years, 0% pediatric adrenal insufficiency in double-blind study and 1.6% in adults, slowing of bone-age advancement in prepubertal subset (predicted adult height gain >2 inches), ~70% of adults brought into physiologic steroid range, and ~40% of overweight/obese adults lost ≥5% body weight over 2 years.

INGREZZA Receptor-Occupancy Edge vs Competitor

Head-to-head PET data showed INGREZZA produced nearly twofold higher VMAT2 target occupancy versus AUSTEDO XR at therapeutic doses, supporting differentiated efficacy claims.

Strong Cash Position and Profitability

Cash and investments rose by approximately $700 million to $2.5 billion at year-end 2025 (from $1.8 billion), and the company delivered ~30% non-GAAP operating margin (~$850 million non-GAAP operating income) in 2025.

Productivity and Pipeline Momentum

2025 was the most productive clinical year (met Phase I–III objectives). Pipeline highlights include NBI-'890 entering Phase II (VMAT2 follow-on), NBI-'675 advancing, and two late-stage Phase III neuropsychiatry programs (osavampator in MDD and direclidine in schizophrenia) with top-line data expected in 2027.

Commercial Investments to Drive Growth

Planned sales force expansions for both INGREZZA and CRENESSITY (CRENESSITY field additions deploying in April 2026) and investments in AI/patient-finding and medical education aimed at expanding reach into endocrinology and non-endocrinology prescribers.

Neurocrine (NBIX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NBIX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 06, 2026	2026 (Q1)	1.15 / -	0.08	―	―	―
Feb 11, 2026	2025 (Q4)	1.80 / 1.48	1	48.00% (+0.48)
Oct 28, 2025	2025 (Q3)	1.59 / 2.04	1.24	64.52% (+0.80)
Jul 30, 2025	2025 (Q2)	0.96 / 1.06	0.63	68.25% (+0.43)
May 05, 2025	2025 (Q1)	0.54 / 0.08	0.42	-80.95% (-0.34)
Feb 06, 2025	2024 (Q4)	1.61 / 1.00	1.44	-30.56% (-0.44)
Oct 30, 2024	2024 (Q3)	1.49 / 1.24	0.82	51.22% (+0.42)
Aug 01, 2024	2024 (Q2)	1.13 / 0.63	0.95	-33.68% (-0.32)
May 01, 2024	2024 (Q1)	1.10 / 0.42	-0.79	153.16% (+1.21)
Feb 07, 2024	2023 (Q4)	1.21 / 1.44	0.88	63.64% (+0.56)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NBIX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 11, 2026	$137.44	$123.10	-10.43%
Oct 28, 2025	$147.38	$138.02	-6.35%
Jul 30, 2025	$136.76	$128.23	-6.24%
May 05, 2025	$109.75	$118.92	+8.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neurocrine (NBIX) report earnings?

Neurocrine (NBIX) is schdueled to report earning on May 06, 2026, After Close (Confirmed).

What is Neurocrine (NBIX) earnings time?

Neurocrine (NBIX) earnings time is at May 06, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NBIX EPS forecast?

NBIX EPS forecast for the fiscal quarter 2026 (Q1) is 1.15.